Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences Inc (NQ: ENVB )

0.3711 -0.0366 (-8.98%)
Streaming Delayed Price Updated: 10:44 AM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115,415
Open 0.4077
Bid (Size) 0.3701 (11)
Ask (Size) 0.3749 (1)
Prev. Close 0.4077
Today's Range 0.3700 - 0.4250
52wk Range 0.3608 - 2.920
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M. 
Via Benzinga
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
From Enveric Biosciences, Inc.
Via Business Wire

Performance

YTD
-70.55%
-70.55%
1 Month
-9.93%
-9.93%
3 Month
-24.27%
-24.27%
6 Month
-52.91%
-52.91%
1 Year
-75.26%
-75.26%

More News

Read More
Enveric Biosciences Announces Broad Range of Patent Issuances
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
From Enveric Biosciences
Via Business Wire
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
Via Benzinga
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
From Enveric Biosciences
Via Business Wire
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
Via Benzinga
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
From Enveric Biosciences
Via Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
Via InvestorPlace
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Why Is Imunon (IMNN) Stock Up 259% Today?
Via InvestorPlace
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
Via Benzinga
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
From Enveric Biosciences
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.